HT
ALNY icon

Headlands Technologies’s Alnylam Pharmaceuticals ALNY Stock Holding History

Headlands Technologies’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,345
Closed -$535K – 723
2025
Q4 		$535K Sell
1,345
-8,847
-87% -$3.92M 0.04% 385
2025
Q3 		$4.65M Buy
+10,192
New +$4.15M 0.37% 61
2024
Q2 		– Sell
-3,150
Closed -$471K – 1124
2024
Q1 		$471K Buy
+3,150
New +$525K 0.11% 203
2023
Q4 		– Sell
-1,146
Closed -$203K – 939
2023
Q3 		$203K Sell
1,146
-1,518
-57% -$290K 0.1% 200
2023
Q2 		$506K Buy
+2,664
New +$528K 0.16% 153

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Headlands Technologies's ALNY Position: Q1 2026 in Review

Headlands Technologies sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 1,345 shares — an estimated $535K sold.

Headlands Technologies first reported a position in ALNY in Q2 2023 and held it in 5 quarters. The position peaked at $4.65M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Headlands Technologies reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Headlands Technologies sold 1,345 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $535K.
  • Headlands Technologies first reported a position in Alnylam Pharmaceuticals in Q2 2023 and held it in 5 quarters.
  • Headlands Technologies's Alnylam Pharmaceuticals position peaked at $4.65M in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Headlands Technologies's 13F filing for Q1 2026, filed 13 May 2026.